PBM
XFOR icon

Propel Bio Management’s X4 Pharmaceuticals XFOR Stock Holding History

Propel Bio Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,833
Closed -$744K – 31
2024
Q1 		$744K Hold
17,833
– – 0.43% 23
2023
Q4 		$449K Buy
+17,833
New +$434K 0.37% 29

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Propel Bio Management's XFOR Position: Q2 2024 in Review

Propel Bio Management sold out of X4 Pharmaceuticals (XFOR) in Q2 2024, closing a stake of 17,833 shares — an estimated $744K sold.

Propel Bio Management first reported a position in XFOR in Q4 2023 and held it in 2 quarters. The position peaked at $744K in Q1 2024. 98 funds tracked by Wall St. Rank hold XFOR as of Q2 2024.

  • Propel Bio Management reported no remaining X4 Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Propel Bio Management sold 17,833 X4 Pharmaceuticals shares in Q2 2024, an estimated $744K.
  • Propel Bio Management first reported a position in X4 Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Propel Bio Management's X4 Pharmaceuticals position peaked at $744K in Q1 2024.
  • 98 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2024.

Based on Propel Bio Management's 13F filing for Q2 2024, filed 12 Aug 2024.